SRPT

Rating neutralAI Memo

Sarepta Therapeutics

As of 2026-08-17/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-17 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

6‑12m

Key catalyst

Potential traditional-approval decisions for AMONDYS 45 and VYONDYS 53 • 2027-02-28

Base target: $22 / p=52% prob

Biggest risk

ELEVIDYS weakness, narrowed product guidance, binary regulatory outcomes, and unproven clinical efficacy could keep the stock under pressure. Clinical readouts may disappoint or be delayed, while leadership transition adds execution risk.

Invalidation

Break below $12 or thesis failure.

What would change my mind?

Sarepta combines positive Q2 operating income, a commercial Duchenne portfolio, upcoming DM1/FSHD data, and potential PMO approval conversions. The $22.087 median target is above the $18.10 anchor price, but the target count is unavailable.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-08-17

Base target

$22

p=52%

Bull target

$28

p=24%

Bear target

$12

p=24%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q2 profitability offsets mixed commercial signal
DM1 and FSHD siRNA clinical readouts
Sarepta combines positive Q2 operating income, a commercial Duchenne portfolio, upcoming DM1/FSHD data, and potential PMO approval conversions.

BearKey bullets

AMONDYS 45 and VYONDYS 53 approval conversions are binary regulatory outcomes.
DM1 and FSHD programs have early biomarker evidence but no established efficacy or durability.
ELEVIDYS commercial weakness and narrowed full-year product guidance could pressure revenue expectations.

WatchKey bullets

Potential traditional-approval decisions for AMONDYS 45 and VYONDYS 53

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $22 (p=52%)

Target spread vs base: +27% / -45%

Scenario probabilities

Bull Target: $28 (p=24%)Base Target: $22 (p=52%)Bear Target: $12 (p=24%)

Commentary

Recent coverage is mixed: Q2 profitability, pipeline milestones, and regulatory progress are constructive, while ELEVIDYS weakness and narrowed guidance are negative. Social, options, short-interest, employee-rating, and verified post-release price-reaction data are unavailable; low coverage and broad peers limit confidence. [#SEC-8K-2026-08-05] [#PR-EARNINGS-2026-08-13]

As of 2026-08-17 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q2 profitability offsets mixed commercial signal
DM1 and FSHD siRNA clinical readouts

Scenarios

Bull Target (Scenario probability)

$28 / p=24% prob

Base Target (Scenario probability)

$22 / p=52% prob

Bear Target (Scenario probability)

$12 / p=24% prob

Analysis 2026-08-17 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.05

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2027-02-28
Potential traditional-approval decisions for AMONDYS 45 and VYONDYS 53
The FDA accepted supplemental applications seeking conversion of AMONDYS 45 and VYONDYS 53 from accelerated to traditional approval. The outcome is binary; stored earnings context indicates a potential decision window around February 2027. [#SEC-8K-2026-08-05] [#PR-EARNINGS-2026-08-13]
Prob 45.00% • Move 25.00% • Priced-in 30.00%

Short-term Catalysts

Next few weeks

Q2 profitability offsets mixed commercial signal
2026-08-17
Q2 2026 net product revenue was $328.7 million, with GAAP and non-GAAP operating income of $13.3 million and $86.5 million. Profitability is constructive, but ELEVIDYS weakness and narrowed full-year product guidance leave near-term sentiment mixed. [#SEC-8K-2026-08-05]
Prob 65% • Move 8% • Priced-in 70%

Long-term Catalysts

Months to a year

DM1 and FSHD siRNA clinical readouts
2026-12-31
MAD-cohort readouts from Phase 1/2 DM1 and FSHD studies remain on track for the second half of 2026. Early exposure and biomarker signals are encouraging, but efficacy and durability remain unproven. [#SEC-8K-2026-08-05]
Prob 45% • Move 30% • Priced-in 25%

Risks

AMONDYS 45 and VYONDYS 53 approval conversions are binary regulatory outcomes.
DM1 and FSHD programs have early biomarker evidence but no established efficacy or durability.
ELEVIDYS commercial weakness and narrowed full-year product guidance could pressure revenue expectations. [#SEC-8K-2026-08-05]
ENDEAVOR Cohort 8 enrollment, safety management, and future ELEVIDYS expansion remain execution-dependent.
The CEO transition became effective in July 2026 and may add near-term execution uncertainty. [#SEC-8K-2026-08-05]

Peers

Symbol	Summary
AMGN	Large-cap biopharma comparator with materially greater scale; useful for sector context but not a direct rare-disease or gene-therapy operating peer.
GILD	Large-cap biopharma reference with greater commercial scale; broad sector context only, with no packet evidence of comparable Sarepta modality or indication exposure.
REGN	Scaled biotechnology comparator; relevant for sector context but not a close match for Sarepta's Duchenne and siRNA portfolio.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-17

Loading AI feed…

Symbol

Summary

AMGN

Large-cap biopharma comparator with materially greater scale; useful for sector context but not a direct rare-disease or gene-therapy operating peer.

GILD

Large-cap biopharma reference with greater commercial scale; broad sector context only, with no packet evidence of comparable Sarepta modality or indication exposure.

REGN

Scaled biotechnology comparator; relevant for sector context but not a close match for Sarepta's Duchenne and siRNA portfolio.